Leniolisib Phosphate Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 70 mg
Reference Brands: Joenja (USA/EU)
Category:
Immune Disorder
Leniolisib phosphate is available in Tablets
and strengths such as 70 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Leniolisib phosphate is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Leniolisib phosphate can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Leniolisib phosphate, marketed under the brand name Joenja, is a targeted kinase inhibitor used for the treatment of activated phosphoinositide 3-kinase delta syndrome (APDS). It is indicated for patients aged twelve years and older who are diagnosed with this rare primary immunodeficiency disorder. APDS is caused by mutations in the PIK3CD or PIK3R1 genes, which play a critical role in regulating the development and function of immune cells.
These genetic abnormalities lead to impaired maturation of B cells and T cells, resulting in weakened immune responses and an increased susceptibility to recurrent bacterial and viral infections. Leniolisib phosphate works by selectively inhibiting the PI3Kδ enzyme, helping to restore balance in immune signaling pathways and improve immune cell function. Unlike broad immunosuppressive therapies, this targeted approach addresses the underlying molecular mechanism of the disease.
Leniolisib phosphate is administered orally and is intended for long-term management under specialist supervision. As a precision therapy developed for a genetically defined condition, its use requires appropriate diagnostic confirmation and ongoing clinical monitoring to ensure safety and therapeutic effectiveness.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing